Stéphane Potvin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7958651/publications.pdf

Version: 2024-02-01

171 papers 6,541 citations

38 h-index 72 g-index

179 all docs

179 docs citations

179 times ranked

8755 citing authors

#	Article	IF	CITATIONS
1	Impact of early use of long-acting injectable antipsychotics on functional outcome in first episode psychosis: a 3-year longitudinal study. International Journal of Psychiatry in Clinical Practice, 2023, 27, 25-34.	1.2	2
2	Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: A Systematic Review and Recommendations of Cannabis use in Bipolar Disorder and Major Depressive Disorder. Canadian Journal of Psychiatry, 2023, 68, 299-311.	0.9	5
3	Developmental multi-trajectory of irritability, anxiety, and hyperactivity as psychological markers of heterogeneity in childhood aggression. Psychological Medicine, 2022, 52, 241-250.	2.7	7
4	Psychosocial Profiles of Patients Admitted to Psychiatric Emergency Services: Results from the Signature Biobank Project. Canadian Journal of Psychiatry, 2022, 67, 380-390.	0.9	1
5	Multiple developmental pathways underlying conduct problems: A multitrajectory framework. Development and Psychopathology, 2022, 34, 1115-1124.	1.4	4
6	Evidence on the acute and residual neurocognitive effects of cannabis use in adolescents and adults: a systematic metaâ€review of metaâ€analyses. Addiction, 2022, 117, 1857-1870.	1.7	30
7	Increased cingulo-orbital connectivity is associated with violent behaviours in schizophrenia. Journal of Psychiatric Research, 2022, 147, 183-189.	1.5	7
8	A methodological checklist for fMRI drug cue reactivity studies: development and expert consensus. Nature Protocols, 2022, 17, 567-595.	5 . 5	26
9	Prediction of quality of life in schizophrenia using machine learning models on data from Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. NPJ Schizophrenia, 2022, 8, 29.	2.0	5
10	Development of the French version of the Davos Assessment of Cognitive Biases Scale in a non linical sample of young adults. Microbial Biotechnology, 2022, , .	0.9	2
11	Meta-analytical transdiagnostic neural correlates in common pediatric psychiatric disorders. Scientific Reports, 2022, 12, 4909.	1.6	6
12	Neural alterations of emotion processing in atypical trajectories of psychotic-like experiences. NPJ Schizophrenia, 2022, 8 , .	2.0	2
13	Acute effects of ketamine and esketamine on cognition in healthy subjects: A meta-analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2022, 118, 110575.	2.5	11
14	Acute effects of partial CB1 receptor agonists on cognition $\hat{a} \in A$ meta-analysis of human studies. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 104, 110063.	2.5	19
15	Aggression and delinquent behavior in a large representative sample of high school students: Cannabis use and victimization as key discriminating factors. Psychiatry Research, 2021, 296, 113640.	1.7	4
16	One-year randomized trial comparing virtual reality-assisted therapy to cognitive–behavioral therapy for patients with treatment-resistant schizophrenia. NPJ Schizophrenia, 2021, 7, 9.	2.0	36
17	Functional connectivity abnormalities of the long-axis hippocampal subregions in schizophrenia during episodic memory. NPJ Schizophrenia, 2021, 7, 19.	2.0	11
18	The Canadian Network for Research in Schizophrenia and Psychoses: A Nationally Focused Approach to Psychosis and Schizophrenia Research. Canadian Journal of Psychiatry, 2021, , 070674372110091.	0.9	2

#	Article	IF	Citations
19	Impaired attentional and socio-affective networks in subjects with antisocial behaviors: a meta-analysis of resting-state functional connectivity studies. Psychological Medicine, 2021, 51, 1249-1259.	2.7	11
20	The processing of angry faces in schizophrenia patients with a history of suicide: An fMRI study examining brain activity and connectivity. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 107, 110253.	2.5	4
21	Functional Connectivity During Visuospatial Processing in Schizophrenia: A Classification Study Using Lasso Regression. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 1077-1087.	1.0	5
22	The therapeutic processes of avatar therapy: A content analysis of the dialogue between treatmentâ€resistant patients with schizophrenia and their avatar. Clinical Psychology and Psychotherapy, 2021, 28, 500-518.	1.4	14
23	Down and High: Reflections Regarding Depression and Cannabis. Frontiers in Psychiatry, 2021, 12, 625158.	1.3	16
24	Cannabis and Cognitive Functioning: From Acute to Residual Effects, From Randomized Controlled Trials to Prospective Designs. Frontiers in Psychiatry, 2021, 12, 596601.	1.3	15
25	A systematic review of longitudinal studies investigating the impact of cannabis use in patients with psychotic disorders. Expert Review of Neurotherapeutics, 2021, 21, 779-791.	1.4	12
26	Does theory of mind predict specific domains of social functioning in individuals following a first episode psychosis? Psychiatry Research, 2021, 301, 113933.	1.7	3
27	Distinct patterns of prefrontal cortical disengagement during inhibitory control in addiction: A meta-analysis based on population characteristics. Neuroscience and Biobehavioral Reviews, 2021, 127, 255-269.	2.9	20
28	Cognitive dysfunction and cerebral volumetric deficits in individuals with Alzheimer's disease, alcohol use disorder, and dual diagnosis. Psychiatry Research - Neuroimaging, 2021, 317, 111380.	0.9	8
29	Converting scores between the PANSS and SAPS/SANS beyond the positive/negative dichotomy. Psychiatry Research, 2021, 305, 114199.	1.7	2
30	Current Practices of Electroconvulsive Therapy in Mental Disorders. Journal of ECT, 2021, 37, 119-127.	0.3	35
31	Use of Automated Thematic Annotations for Small Data Sets in a Psychotherapeutic Context: Systematic Review of Machine Learning Algorithms. JMIR Mental Health, 2021, 8, e22651.	1.7	6
32	Editorial: Purple Haze: Issues on Cannabis Legalization. Frontiers in Psychiatry, 2021, 12, 796032.	1.3	1
33	Developmental joint trajectories of anxiety-depressive trait and trait-aggression: implications for co-occurrence of internalizing and externalizing problems. Psychological Medicine, 2020, 50, 1338-1347.	2.7	25
34	Longâ€acting antipsychotic medication as firstâ€ine treatment of firstâ€episode psychosis with comorbid substance use disorder. Microbial Biotechnology, 2020, 14, 69-79.	0.9	24
35	Exploring the Benefits of Virtual Reality-Assisted Therapy Following Cognitive-Behavioral Therapy for Auditory Hallucinations in Patients with Treatment-Resistant Schizophrenia: A Proof of Concept. Journal of Clinical Medicine, 2020, 9, 3169.	1.0	17
36	Neurofunctional abnormalities in antisocial spectrum: A meta-analysis of fMRI studies on Five distinct neurocognitive research domains. Neuroscience and Biobehavioral Reviews, 2020, 119, 168-183.	2.9	38

#	Article	IF	Citations
37	Violence and Cannabis Use: A Focused Review of a Forgotten Aspect in the Era of Liberalizing Cannabis. Frontiers in Psychiatry, 2020, 11, 567887.	1.3	23
38	A Meta-analysis of Mindfulness-Based Interventions in Adults with Attention-Deficit Hyperactivity Disorder: Impact on ADHD Symptoms, Depression, and Executive Functioning. Mindfulness, 2020, 11, 2669-2681.	1.6	19
39	<p>Medial Orbitofrontal De-Activation During Tonic Cold Pain Stimulation: A fMRI Study Examining the Opponent-Process Theory</p> . Journal of Pain Research, 2020, Volume 13, 1335-1347.	0.8	5
40	Peripheral Endogenous Cannabinoid Levels Are Increased in Schizophrenia Patients Evaluated in a Psychiatric Emergency Setting. Frontiers in Psychiatry, 2020, 11, 628.	1.3	16
41	Berkson's bias in biobank sampling in a specialised mental health care setting: a comparative cross-sectional study. BMJ Open, 2020, 10, e035088.	0.8	6
42	Association Between the Use of Cannabis and Physical Violence in Youths: A Meta-Analytical Investigation. American Journal of Psychiatry, 2020, 177, 619-626.	4.0	29
43	Impact of early use of long-acting injectable antipsychotics on psychotic relapses and hospitalizations in first-episode psychosis. International Clinical Psychopharmacology, 2020, 35, 221-228.	0.9	15
44	Violent Behavior Is Associated With Emotion Salience Network Dysconnectivity in Schizophrenia. Frontiers in Psychiatry, 2020, 11, 143.	1.3	11
45	Cognitive biases in individuals with psychotic-like experiences: A systematic review and a meta-analysis. Schizophrenia Research, 2020, 222, 10-22.	1.1	42
46	Limbic Hyperactivity in Response to Emotionally Neutral Stimuli in Schizophrenia: Response to Rasetti et al American Journal of Psychiatry, 2020, 177, 640-641.	4.0	4
47	Interpersonal Risk Factors for Suicide in Cocaine Dependence: Association with Selfâ€Esteem, Personality Traits, and Childhood Abuse. Suicide and Life-Threatening Behavior, 2020, 50, 867-883.	0.9	13
48	Comorbidity Profiles of Psychotic Patients in Emergency Psychiatry. Journal of Dual Diagnosis, 2020, 16, 260-270.	0.7	7
49	Mobile Apps for Mental Health Issues: Meta-Review of Meta-Analyses. JMIR MHealth and UHealth, 2020, 8, e17458.	1.8	169
50	Evidence on Virtual Reality–Based Therapies for Psychiatric Disorders: Meta-Review of Meta-Analyses. Journal of Medical Internet Research, 2020, 22, e20889.	2.1	59
51	Comprehensive review on virtual reality for the treatment of violence: implications for youth with schizophrenia. NPJ Schizophrenia, 2019, 5, 11.	2.0	15
52	Limbic Hyperactivity in Response to Emotionally Neutral Stimuli in Schizophrenia: A Neuroimaging Meta-Analysis of the Hypervigilant Mind. American Journal of Psychiatry, 2019, 176, 1021-1029.	4.0	30
53	The Psychometric Properties of a Short UPPS-P Impulsive Behavior Scale Among Psychiatric Patients Evaluated in an Emergency Setting. Frontiers in Psychiatry, 2019, 10, 139.	1.3	41
54	Mobile Intervention for Individuals With Psychosis, Dual Disorders, and Their Common Comorbidities: A Literature Review. Frontiers in Psychiatry, 2019, 10, 302.	1.3	22

#	Article	IF	CITATIONS
55	Reward-related decision-making in schizophrenia: A multimodal neuroimaging study. Psychiatry Research - Neuroimaging, 2019, 286, 45-52.	0.9	12
56	Cannabis use and violence in patients with severe mental illnesses: A meta-analytical investigation. Psychiatry Research, 2019, 274, 42-48.	1.7	34
57	Can Social Anxiety Impact Facial Emotion Recognition in Schizophrenia?. Journal of Nervous and Mental Disease, 2019, 207, 140-144.	0.5	12
58	Rapid screening for cognitive deficits in attention deficit and hyperactivity disorders with the screen for cognitive impairment in psychiatry. ADHD Attention Deficit and Hyperactivity Disorders, 2019, 11, 139-147.	1.7	5
59	Increased Connectivity Between the Nucleus Accumbens and the Default Mode Network in Patients With Schizophrenia During Cigarette Cravings. Journal of Dual Diagnosis, 2019, 15, 8-15.	0.7	10
60	Predicting and preventing symptom onset and relapse in schizophreniaâ€"A metareview of current empirical evidence Journal of Abnormal Psychology, 2019, 128, 840-854.	2.0	30
61	Virtual reality therapy for refractory auditory verbal hallucinations in schizophrenia: A pilot clinical trial. Schizophrenia Research, 2018, 197, 176-181.	1.1	103
62	Cognitive deficits in individuals with methamphetamine use disorder: A meta-analysis. Addictive Behaviors, 2018, 80, 154-160.	1.7	219
63	Distinct pathological profiles of inmates showcasing cluster B personality traits, mental disorders and substance use regarding violent behaviors. Psychiatry Research, 2018, 260, 371-378.	1.7	7
64	Reduced dorsolateral prefrontal cortex activation during affective Go/NoGo in violent schizophrenia patients: An fMRI study. Schizophrenia Research, 2018, 197, 249-252.	1.1	16
65	The Impact of Pain Invisibility on Patient-Centered Care and Empathetic Attitude in Chronic Pain Management. Pain Research and Management, 2018, 2018, 1-8.	0.7	33
66	Exploration of the dialogue components in <scp>A</scp> vatar <scp>T</scp> herapy for schizophrenia patients with refractory auditory hallucinations: <scp>A</scp> content analysis. Clinical Psychology and Psychotherapy, 2018, 25, 878-885.	1.4	24
67	The prevalence of substance-induced psychotic disorder in methamphetamine misusers: A meta-analysis. Psychiatry Research, 2018, 268, 189-192.	1.7	53
68	History of Suicide Attempt Is Associated with Reduced Medial Prefrontal Cortex Activity during Emotional Decision-Making among Men with Schizophrenia: An Exploratory fMRI Study. Schizophrenia Research and Treatment, 2018, 2018, 1-8.	0.7	15
69	Avatar Therapy for persistent auditory verbal hallucinations: a case report of a peer research assistant on his path toward recovery. Psychosis, 2018, 10, 213-219.	0.4	4
70	Avatar Therapy for Persistent Auditory Verbal Hallucinations in an Ultra-Resistant Schizophrenia Patient: A Case Report. Frontiers in Psychiatry, 2018, 9, 131.	1.3	22
71	Pleasant Pain Relief and Inhibitory Conditioned Pain Modulation: A Psychophysical Study. Pain Research and Management, 2018, 2018, 1-8.	0.7	7
72	Loss anticipation and outcome during the <i>Monetary Incentive Delay Task</i> : a neuroimaging systematic review and meta-analysis. PeerJ, 2018, 6, e4749.	0.9	54

#	Article	IF	Citations
73	Three-Year Naturalistic Study On Early Use Of Long-Acting Injectable Antipsychotics In First Episode Psychosis. Psychopharmacology Bulletin, 2018, 48, 25-61.	0.0	9
74	Reversing the Atypical Valuation of Drug and Nondrug Rewards in Smokers Using Multimodal Neuroimaging. Biological Psychiatry, 2017, 82, 819-827.	0.7	33
75	Functional Neuroimaging Predictors of Self-Reported Psychotic Symptoms in Adolescents. American Journal of Psychiatry, 2017, 174, 566-575.	4.0	32
76	Symptomatic and functional outcomes of substance use disorder persistence 2 years after admission to a first-episode psychosis program. Psychiatry Research, 2017, 247, 113-119.	1.7	54
77	The psychometric properties of the Life History of Aggression evaluated in patients from a psychiatric emergency setting. Psychiatry Research, 2017, 257, 485-489.	1.7	8
78	Abnormal effective fronto-limbic connectivity during emotion processing in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 72, 1-8.	2.5	24
79	The Drug Abuse Screening Test preserves its excellent psychometric properties in psychiatric patients evaluated in an emergency setting. Addictive Behaviors, 2017, 64, 165-170.	1.7	16
80	Impaired Coupling between the Dorsomedial Prefrontal Cortex and the Amygdala in Schizophrenia Smokers Viewing Anti-smoking Images. Frontiers in Psychiatry, 2017, 8, 109.	1.3	2
81	Persistency of Cannabis Use Predicts Violence following Acute Psychiatric Discharge. Frontiers in Psychiatry, 2017, 8, 176.	1.3	40
82	Markedly Reduced Thermal Pain Perception in a Schizoaffective Patient with Tardive Dyskinesia. Case Reports in Psychiatry, 2016, 2016, 1-3.	0.2	1
83	Anterior cingulate hyperactivations during negative emotion processing among men with schizophrenia and a history of violent behavior. Neuropsychiatric Disease and Treatment, 2016, 12, 1397.	1.0	19
84	Emotionally Neutral Stimuli Are Not Neutral in Schizophrenia: A Mini Review of Functional Neuroimaging Studies. Frontiers in Psychiatry, 2016, 7, 115.	1.3	24
85	Pain facilitation and pain inhibition during conditioned pain modulation in fibromyalgia and in healthy controls. Pain, 2016, 157, 1704-1710.	2.0	123
86	The Prevalence of Electroconvulsive Therapy Use Since 1973. Journal of ECT, 2016, 32, 236-242.	0.3	34
87	Self-evaluation and objective assessment of cognition in major depression and attention deficit disorder: Implications for clinical practice. Comprehensive Psychiatry, 2016, 70, 53-64.	1.5	43
88	Increased spinal pain sensitization in major depressive disorder: A pilot study. Psychiatry Research, 2016, 246, 756-761.	1.7	6
89	Increased ventro-medial prefrontal activations in schizophrenia smokers during cigarette cravings. Schizophrenia Research, 2016, 173, 30-36.	1.1	20
90	The Role of Appetitive and Aversive Smoking Cues in Tobacco Use Disorder with a Focus on fMRI. , 2016, , 291-304.		1

#	Article	IF	Citations
91	Neuroimaging of cigarette cravings: individual differences matter. Addiction, 2015, 110, 204-205.	1.7	1
92	Response to: A Commentary on "Antipsychotic-Induced Parkinsonism is Associated with Working Memory Deficits in Schizophrenia-Spectrum Disorders― Frontiers in Behavioral Neuroscience, 2015, 9, 210.	1.0	0
93	Cigarette Cravings, Impulsivity, and the Brain. Frontiers in Psychiatry, 2015, 6, 125.	1.3	22
94	Psychopathology in Substance Use Disorder Patients with and without Substance-Induced Psychosis. Journal of Addiction, 2015, 2015, 1-7.	0.9	14
95	Assessing Patient-Centred Care for Chronic Pain: Validation of a New Research Paradigm. Pain Research and Management, 2015, 20, 183-188.	0.7	8
96	Anandamide Is Involved in Appetite-Related Amygdala Hyperactivations in Schizophrenia Patients Treated With Olanzapine. Journal of Clinical Psychopharmacology, 2015, 35, 82-83.	0.7	3
97	Emotion processing in treatment-resistant schizophrenia patients treated with clozapine: An fMRI study. Schizophrenia Research, 2015, 168, 377-380.	1.1	18
98	Sex differences in effective fronto-limbic connectivity during negative emotion processing. Psychoneuroendocrinology, 2015, 62, 180-188.	1.3	62
99	Antipsychotic-induced parkinsonism is associated with working memory deficits in schizophrenia-spectrum disorders. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 147-154.	1.8	12
100	Assessing patient-centered care: Validation of the French Version of the Patient-Practitioner Orientation Scale (PPOS). European Journal for Person Centered Healthcare, 2015, 3, 295.	0.3	3
101	The 10th Anniversary of the Eli Lilly Chair of Schizophrenia from the University of Montreal. Canadian Journal of Psychiatry, 2015, 60, S1-4.	0.9	0
102	Antipsychotic-induced changes in blood levels of leptin in schizophrenia: a meta-analysis. Canadian Journal of Psychiatry, 2015, 60, S26-34.	0.9	42
103	Sex Differences and Menstrual Cycle Phase-Dependent Modulation of Craving for Cigarette: An fMRI Pilot Study. Psychiatry Journal, 2014, 2014, 1-7.	0.7	21
104	Striatum Inhibition: Clues for Cocaine Addiction Therapy. Canadian Journal of Neurological Sciences, 2014, 41, 664-665.	0.3	0
105	Executive-affective connectivity in smokers viewing anti-smoking images: An fMRI study. Psychiatry Research - Neuroimaging, 2014, 224, 262-268.	0.9	11
106	Cocaine and Cognition. Journal of Addiction Medicine, 2014, 8, 368-376.	1.4	159
107	Where there's smoke, there's fire: The brain reactivity of chronic smokers when exposed to the negative value of smoking. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 50, 66-73.	2.5	12
108	Drugs of abuse and psychiatric disorders: Neurobiological and clinical aspects. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 52, 1-3.	2.5	3

#	Article	IF	CITATIONS
109	Is there a binding deficit in working memory in patients with schizophrenia? A meta-analysis. Schizophrenia Research, 2014, 158, 142-145.	1.1	2
110	Male Inmate Profiles and Their Biological Correlates. Canadian Journal of Psychiatry, 2014, 59, 441-449.	0.9	19
111	Widespread and sustained cognitive deficits in alcoholism: a metaâ€analysis. Addiction Biology, 2013, 18, 203-213.	1.4	433
112	Predictors of Community Functioning in Schizophrenia and Substance Use Disorder Patients. Community Mental Health Journal, 2013, 49, 317-322.	1.1	6
113	Antipsychotics' effects on blood levels of cytokines in schizophrenia: A meta-analysis. Schizophrenia Research, 2013, 151, 43-47.	1.1	190
114	Cannabis abuse is associated with better emotional memory in schizophrenia: A functional magnetic resonance imaging study. Psychiatry Research - Neuroimaging, 2013, 214, 24-32.	0.9	14
115	The Neural Correlates of Mental Rotation Abilities in Cannabis-Abusing Patients with Schizophrenia: An fMRI Study. Schizophrenia Research and Treatment, 2013, 2013, 1-10.	0.7	11
116	Neural Circuitry of Impulsivity in a Cigarette Craving Paradigm. Frontiers in Psychiatry, 2013, 4, 67.	1.3	20
117	Modulation of the Endocannabinoid System: Vulnerability Factor and New Treatment Target for Stimulant Addiction. Frontiers in Psychiatry, 2013, 4, 109.	1.3	34
118	Cannabidiol in Humans—The Quest for Therapeutic Targets. Pharmaceuticals, 2012, 5, 529-552.	1.7	155
119	Questioning the Specificity of ASRS-v1.1 to Accurately Detect ADHD in Substance Abusing Populations. Journal of Attention Disorders, 2012, 16, 661-663.	1.5	22
120	Add-on Treatment of Quetiapine for Fibromyalgia. Journal of Clinical Psychopharmacology, 2012, 32, 684-687.	0.7	23
121	Temporal Summation of Pain Is Not Amplified in a Large Proportion of Fibromyalgia Patients. Pain Research and Treatment, 2012, 2012, 1-6.	1.7	29
122	Paradoxical Cognitive Capacities in Dual Diagnosis Schizophrenia: The Quest for Explanatory Factors. Journal of Dual Diagnosis, 2012, 8, 35-47.	0.7	22
123	Sensation-seeking, social anhedonia, and impulsivity in substance use disorder patients with and without schizophrenia and in non-abusing schizophrenia patients. Psychiatry Research, 2012, 200, 237-241.	1.7	40
124	Pain Perception in Schizophrenia: Evidence of a Specific Pain Response Profile. Pain Medicine, 2012, 13, 1571-1579.	0.9	44
125	Plasma Endocannabinoid Alterations in Individuals with Substance Use Disorder are Dependent on the "Mirror Effect―of Schizophrenia. Frontiers in Psychiatry, 2012, 3, 85.	1.3	19
126	Is the Deficit in Pain Inhibition in Fibromyalgia Influenced by Sleep Impairments?. Open Rheumatology Journal, 2012, 6, 296-302.	0.1	46

#	Article	IF	CITATIONS
127	<i>In vivo</i> immunomodulatory effects of antipsychotics on inflammatory mediators: A review. Advances in Bioscience and Biotechnology (Print), 2012, 03, 551-565.	0.3	10
128	Is the Mood Disorder Questionnaire an appropriate screening tool in detecting bipolar spectrum disorder among substance use populations?. American Journal of Drug and Alcohol Abuse, 2011, 37, 79-81.	1.1	2
129	Schizophrenia and serious violence: A clinical-profile analysis incorporating impulsivity and substance-use disorders. Schizophrenia Research, 2011, 130, 234-237.	1.1	44
130	Soluble interleukin-2 receptor levels correlated with positive symptoms during quetiapine treatment in schizophrenia-spectrum disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 1695-1698.	2.5	26
131	Evolution of Substance use, Neurological and Psychiatric Symptoms in Schizophrenia and Substance use Disorder Patients: A 12-Week, Pilot, Case–Control Trial with Quetiapine. Frontiers in Psychiatry, 2011, 2, 22.	1.3	12
132	A Deficit in Peripheral Serotonin Levels in Major Depressive Disorder but Not in Chronic Widespread Pain. Clinical Journal of Pain, 2011, 27, 529-534.	0.8	27
133	Dose-response and comparative efficacy and tolerability of quetiapine across psychiatric disorders. International Clinical Psychopharmacology, 2011, 26, 183-192.	0.9	39
134	Ziprasidone for Psychotic Disorders: A Meta-Analysis and Systematic Review of the Relationship Between Pharmacokinetics, Pharmacodynamics, and Clinical Profile. Clinical Therapeutics, 2011, 33, 1853-1867.	1.1	14
135	Pain Inhibition Is Deficient in Chronic Widespread Pain but Normal in Major Depressive Disorder. Journal of Clinical Psychiatry, 2011, 72, 219-224.	1.1	94
136	Inflammatory alterations in dual diagnosis patients with schizophrenia and substance use disorders. FASEB Journal, 2011, 25, .	0.2	0
137	Antipsychotic Agents for the Treatment of Substance Use Disorders in Patients With and Without Comorbid Psychosis. Journal of Clinical Psychopharmacology, 2010, 30, 417-424.	0.7	34
138	Extrapyramidal symptoms in substance abusers with and without schizophrenia and in nonabusing patients with schizophrenia. Movement Disorders, 2010, 25, 2188-2194.	2.2	21
139	No relationship between the ins del polymorphism of the serotonin transporter promoter and pain perception in fibromyalgia patients and healthy controls. European Journal of Pain, 2010, 14, 742-746.	1.4	59
140	Endocannabinoids and Schizophrenia. Pharmaceuticals, 2010, 3, 3101-3126.	1.7	27
141	Quetiapine blocks cocaine-induced enhancement of brain stimulation reward. Behavioural Brain Research, 2010, 208, 163-168.	1.2	18
142	Switching from conventional antipsychotics to ziprasidone: A randomized, open-label comparison of regimen strategies. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 997-1000.	2.5	14
143	Clinical evolution of substance use disorder patients during treatment with quetiapine: a 12-week, open-label, naturalistic trial. Expert Opinion on Pharmacotherapy, 2010, 11, 2947-2951.	0.9	4
144	Pain relief through expectation supersedes descending inhibitory deficits in fibromyalgia patients. Pain, 2009, 145, 18-23.	2.0	55

#	Article	IF	Citations
145	Fibromyalgia subgroups: profiling distinct subgroups using the Fibromyalgia Impact Questionnaire. A preliminary study. Rheumatology International, 2009, 29, 509-515.	1.5	74
146	Human evidence of a supraâ€spinal modulating role of dopamine on pain perception. Synapse, 2009, 63, 390-402.	0.6	118
147	Substance abuse is associated with increased extrapyramidal symptoms in schizophrenia: A meta-analysis. Schizophrenia Research, 2009, 113, 181-188.	1.1	35
148	DRD3 Ser9Gly Polymorphism Is Related to Thermal Pain Perception and Modulation in Chronic Widespread Pain Patients and Healthy Controls. Journal of Pain, 2009, 10, 969-975.	0.7	91
149	The Deficit of Pain Inhibition in Fibromyalgia Is More Pronounced in Patients With Comorbid Depressive Symptoms. Clinical Journal of Pain, 2009, 25, 123-127.	0.8	118
150	Pain perception in schizophrenia: No changes in diffuse noxious inhibitory controls (DNIC) but a lack of pain sensitization. Journal of Psychiatric Research, 2008, 42, 1010-1016.	1.5	67
151	Contradictory cognitive capacities among substance-abusing patients with schizophrenia: A meta-analysis. Schizophrenia Research, 2008, 100, 242-251.	1.1	128
152	Inflammatory Cytokine Alterations in Schizophrenia: A Systematic Quantitative Review. Biological Psychiatry, 2008, 63, 801-808.	0.7	883
153	Hypoalgesia in schizophrenia is independent of antipsychotic drugs: A systematic quantitative review of experimental studies. Pain, 2008, 138, 70-78.	2.0	88
154	Anhedonia and Social Adaptation Predict Substance Abuse Evolution in Dual Diagnosis Schizophrenia. American Journal of Drug and Alcohol Abuse, 2008, 34, 75-82.	1.1	17
155	Working memory and depressive symptoms in patients with schizophrenia and substance use disorders. Cognitive Neuropsychiatry, 2008, 13, 357-366.	0.7	22
156	Analgesic and antihyperalgesic effects of nabilone on experimental heat pain. Current Medical Research and Opinion, 2008, 24, 1017-1024.	0.9	49
157	Endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy. Journal of Psychopharmacology, 2008, 22, 262-269.	2.0	45
158	Cannabis and Psychosis: What is the Link?. Journal of Psychoactive Drugs, 2007, 39, 131-142.	1.0	37
159	Meta-Analysis of Depressive Symptoms in Dual-Diagnosis Schizophrenia. Australian and New Zealand Journal of Psychiatry, 2007, 41, 792-799.	1.3	39
160	Computerized assessment of cognition in schizophrenia: Promises and pitfalls of CANTAB. European Psychiatry, 2007, 22, 104-115.	0.1	139
161	Processing of social emotion in patients with schizophrenia and substance use disorder: An fMRI study. Social Neuroscience, 2007, 2, 106-116.	0.7	17
162	Increased striatal gray matter densities in patients with schizophrenia and substance use disorder: A voxel-based morphometry study. Psychiatry Research - Neuroimaging, 2007, 154, 275-279.	0.9	21

STéPHANE POTVIN

#	Article	IF	CITATIONS
163	Selective Serotonin Reuptake Inhibitor (SSRI) Add-On Therapy for the Negative Symptoms of Schizophrenia. Journal of Clinical Psychiatry, 2007, 68, 604-610.	1.1	86
164	A meta-analysis of negative symptoms in dual diagnosis schizophrenia. Psychological Medicine, 2006, 36, 431-440.	2.7	108
165	Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: an open-label trial. Current Medical Research and Opinion, 2006, 22, 1277-1285.	0.9	63
166	The Paradox of Quetiapine in Obsessive-Compulsive Disorder. CNS Spectrums, 2005, 10, 356-361.	0.7	25
167	Toxic Psychoses as Pharmacological Models of Schizophrenia. Current Psychiatry Reviews, 2005, 1, 23-32.	0.9	10
168	CANTAB explicit memory is less impaired in addicted schizophrenia patients. Brain and Cognition, 2005, 59, 38-42.	0.8	63
169	Clozapine, quetiapine and olanzapine among addicted schizophrenic patients. International Clinical Psychopharmacology, 2003, 18, 121-132.	0.9	54
170	Des repères pour la conception des apps�. Sante Mentale Au Quebec, 0, 46, 119-134.	0.1	1
171	The Potential Paradoxical Neurocognitive Effects of Cannabis Use in Patients with Psychotic Disorders: A Critical Meta-Review of Meta-Analytical Evidence. Cannabis and Cannabinoid Research, 0, ,	1.5	0